Journal of Cancer 2024

13 papers
The 2024 edition of the Journal of Cancer highlights research focused on multi-omic integration and clinical predictive modeling. Key research directions include the application of bulk and single-cell transcriptomics for clinical discovery, alongside the validation of multi-omic and radiomic biomarkers. Studies frequently utilize visual nomograms for clinical risk prediction and explore molecular signaling pathways driving tumor dynamics. Specific investigations address the role of METTL3 in colorectal cancer and the impact of ALDH1A1 expression in intrahepatic cholangiocellular carcinoma. The year's publications also emphasize diagnostic and therapeutic innovations, such as nanotechnology applications for gliomas and the use of circulating microRNA panels for pancreatic ductal adenocarcinoma. Clinical insights from multi-parameter immune phenotyping and strategies to overcome multidrug resistance are central themes. Notable work includes meta-analyses on high-dose-rate brachytherapy for localized prostate cancer and reviews of prostate cancer stem cells. Prolific contributors to this volume include researchers such as Huiqin Lu, Jielin Zhang, and Kaichen Zhou, who have contributed to the understanding of the immune landscape and prognostic markers across various malignancies.

Top Research Directions

The 57 research directions with Journal of Cancer 2024 papers, ranked by paper count, next to 2023. Share is the fraction of the edition’s papers in the direction.

#Direction20242023Share 2024Share 20232023 rank
1In Vivo Xenograft Models for Preclinical Cancer Research2015.4%0.0%—
2Molecular Biomarkers for Independent Cancer Risk Stratification2015.4%0.0%—
3Multicellular Ecosystems and Ecotypes in the Tumor Microenvironment2015.4%0.0%—
4Proteomic Biomarkers for Cancer Prognosis and Treatment Response2015.4%0.0%—
5Transcriptome Wide Mapping of RNA Modifications2015.4%0.0%—
6Composite Multi-Marker Diagnostic Panels107.7%0.0%—
7Computational Deconvolution of the Tumor Microenvironment107.7%0.0%—
8Cross Platform Validation of Transcriptomic Biomarkers107.7%0.0%—
9Epigenetic Gene Silencing via Promoter Hypermethylation107.7%0.0%—
10Epitranscriptomic Regulation of Tumor Growth and Immune Evasion107.7%0.0%—
11Evaluating Clinical Outcomes Using Historical Patient Cohorts107.7%0.0%—
12Exonuclease Resistance in Circulating RNA Biomarkers107.7%0.0%—
13Finding Optimal Cutoffs for Continuous Biomarkers107.7%0.0%—
14Functional Validation Requirements for Bioinformatic Biomarkers107.7%0.0%—
15How Chronic Inflammation Triggers Malignant Transformation and Progression107.7%0.0%—
16Identifying Molecular Vulnerabilities for Tumor Growth Suppression107.7%0.0%—
17Integrating Bulk and Single-Cell Transcriptomics107.7%0.0%—
18Integrating Diagnostic Imaging and Targeted Therapy107.7%0.0%—
19Interpreting Gene Expression via Functional Enrichment Analysis107.7%0.0%—
20Long-Term Clearance and Bioaccumulation of Therapeutic Nanomaterials107.7%0.0%—
21Mapping Molecular Pathways via Epistatic Rescue Assays107.7%0.0%—
22Molecular and Computational Strategies for Early Pancreatic Cancer Detection107.7%0.0%—
23Molecular Cascades Driving Cancer Metastasis117.7%20.0%8
24Molecular Mechanisms of Sex Differences in Cancer107.7%0.0%—
25Molecular Mechanisms of the Epithelial Mesenchymal Transition107.7%0.0%—

Download all directions as CSV

Institutions

Institutions credited by Journal of Cancer 2024 papers: a paper credits every institution named in its affiliations, once. 38 institutions share 13 credited papers.

#InstitutionPapersShare20232023 rank
1Tongji University 215.4%0—
2001rahr89 17.7%0—
300g2rqs52 17.7%0—
401ey7we33 17.7%0—
501f77gp95 17.7%0—
6038xmzj21 17.7%0—
703dveyr97 17.7%17
803ekhbz91 17.7%0—
9043ea4m21 17.7%0—
1004cjrj888 17.7%0—
1104py1g812 17.7%0—
12052vn2478 17.7%0—
13056ef9489 17.7%0—
1405jb9pq57 17.7%0—
1505xceke97 17.7%0—
16Academia Sinica 17.7%0—
17Anhui Medical University 17.7%0—
18China Three Gorges University 17.7%0—
19Chinese Academy of Medical Sciences & Peking Union Medical College 17.7%0—
20First Hospital of Shanxi Medical University 17.7%0—
21German Cancer Research Center 17.7%0—
22Harbin Medical University 17.7%0—
23Nanjing University 17.7%0—
24Nanjing University of Chinese Medicine 17.7%0—
25Nantong University 17.7%0—
26Peking Union Medical College Hospital 17.7%0—
27Peking University First Hospital 17.7%0—
28Ruijin Hospital 17.7%0—
29Shandong University 17.7%0—
30Shanghai First People's Hospital 17.7%0—

Download all institutions as CSV

About this data

Papers. Journal of Cancer 2024 lists 13 papers on Lacuna, duplicate versions counted once; rejected and withdrawn submissions are left out.

Directions. Directions are Lacuna’s clustering of the concept elements extracted from each paper, so a paper can belong to several and direction counts add up to more than the paper count. A direction’s share is its papers divided by the edition’s papers. Comparisons with 2023 use shares, since the edition went from 5 to 13 papers.

Institutions. A paper credits each institution named in its affiliations, resolved to a ROR record, once. 13 of 13 papers (100.0%) credit at least one institution and are the base for institution shares; the rest have no resolved affiliation yet.

Data. Counts come from Lacuna’s data build of 2026-11-18 and change as papers are added. Tables as CSV: directions · institutions. Cite as: Lacuna, “Journal of Cancer 2024”, https://lacuna.tiptreesystems.com/venue/journal-of-cancer/2024.

Top Authors

AuthorPapers
Yichuan Zhao1

Impactful Papers

Papers from Journal of Cancer 2024 that shaped research clusters.

Influential

Papers

Title
ADAMTS7 Enhances Gastric Cancer Growth and Metastasis by Triggering the NF-κB Signaling Pathway
Contribution of a Circulating 2'-O-methylated MicroRNA Panel to the Diagnosis of Pancreatic Ductal Adenocarcinoma
High Expression of RAB32 Predicts Adverse Outcomes: A Potential Therapeutic Target for Glioblastoma
IPCEF1: Expression Patterns, Clinical Correlates and New Target of Papillary Thyroid Carcinoma
Impact of ALDH1A1 Expression in Intrahepatic Cholangiocellular Carcinoma
Induction of interleukin-6 by SPZ1-mediated Wnt5a signaling boosts progression of nasopharyngeal carcinoma cells
METTL3 Inhibition Suppresses Cell Growth and Survival in Colorectal Cancer via ASNS Downregulation
Nanotechnology as a new strategy for the diagnosis and treatment of gliomas
Pan-Cancer Analysis of ART1 and its Potential Value in Gastric Cancer
Preoperative Serum Cystatin C as an Independent Prognostic Factor for Survival in Patients with Renal Cell Carcinoma
Prostate cancer stem cells: an updated mini-review
Single-fraction high-dose-rate brachytherapy as monotherapy for localized prostate cancer: long-term follow-up study based on meta-analysis
Unveiling the Prognostic Power and Immune Landscape of MyD88 in Breast Cancer: an Integrative Bioinformatics and IHC Approach